WCLC 2025 - Posters & ePosters-P3.18.45 A Multi-Cohort, Phase II Study of SHR0302 Combined With PD-1/PD-L1 Inhibitior for Treatment Naïve or Acquired Resistant to Immunology NSCLC

P3.18.45 A Multi-Cohort, Phase II Study of SHR0302 Combined With PD-1/PD-L1 Inhibitior for Treatment Naïve or Acquired Resistant to Immunology NSCLC

Asset Subtitle

Xinyu Zhang

Meta Tag

Speaker Xinyu Zhang

Topic Clinical Trials in Progress